Compare · ABT vs AIMD
ABT vs AIMD
Side-by-side comparison of Abbott Laboratories (ABT) and Ainos Inc. (AIMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AIMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.59B, about 9433.4x AIMD ($16.3M).
- Over the past year, ABT is down 34.3% and AIMD is down 26.2% - AIMD leads by 8.1 points.
- AIMD has been more active in the news (12 items in the past 4 weeks vs 7 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- Abbott Laboratories
- Ainos Inc.
- Price
- $88.09-1.73%
- $1.92-2.04%
- Market cap
- $153.59B
- $16.3M
- 1M return
- +5.08%
- +11.63%
- 1Y return
- -34.26%
- -26.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 12
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest AIMD
- Director Chiang Yao-Chung bought $7,175 worth of shares (3,500 units at $2.05) (SEC Form 4)
- Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
- Director Chiang Yao-Chung bought $4,260 worth of shares (2,000 units at $2.13) (SEC Form 4)
- VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations
- Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study
- Director Chiang Yao-Chung bought $575 worth of shares (250 units at $2.30) (SEC Form 4)
- Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis
- Director Chiang Yao-Chung bought $4,000 worth of shares (2,000 units at $2.00) (SEC Form 4)
- Director Lee Ting-Chuan sold $208,977 worth of shares (109,988 units at $1.90), decreasing direct ownership by 12% to 807,417 units (SEC Form 4) to satisfy tax liability
- Large owner Taiwan Carbon Nano Technology Corp sold $96,760 worth of shares (41,000 units at $2.36), decreasing direct ownership by 4% to 948,925 units (SEC Form 4) (withholding obligation)